University of Calgary

Arnie Charbonneau Cancer Institute

Calgary, Alberta

Sorting 1 by

Not yet accepting

EMBRACE

A Study of Elranatamab Management With Outpatient and Intermittent Dosing in Relapsed/Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 2